The pro-atherogenic role of IL-17A has been confirmed by multiple experiments (48), and future studies are needed to further prove whether CTLA-4 inhibition can influence the progression of atherosclerosis through the CXCR4/Th17/IL17A axis. This evidence concerns the gene IL17A and atherosclerosis.